CytomX Therapeutics Management
Management criteria checks 3/4
CytomX Therapeutics' CEO is Sean McCarthy, appointed in Aug 2011, has a tenure of 12.67 years. total yearly compensation is $2.61M, comprised of 25% salary and 75% bonuses, including company stock and options. directly owns 0.78% of the company’s shares, worth $884.94K. The average tenure of the management team and the board of directors is 3 years and 4.3 years respectively.
Key information
Sean McCarthy
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 25.0% |
| CEO tenure | 12.7yrs |
| CEO ownership | 0.8% |
| Management average tenure | 3yrs |
| Board average tenure | 4.3yrs |
Recent management updates
Recent updates
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 85%
Mar 05
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Jan 19There's No Escaping CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Muted Revenues Despite A 27% Share Price Rise
Nov 26We're Hopeful That CytomX Therapeutics (NASDAQ:CTMX) Will Use Its Cash Wisely
Nov 17Newsflash: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 29Can CytomX Therapeutics (NASDAQ:CTMX) Afford To Invest In Growth?
Feb 13Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%
Nov 10CytomX Therapeutics to cut workforce by about 40%
Jul 13CytomX says phase 2 study of breast cancer antibody treatment met main goal
Jul 06Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Jun 08Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?
Feb 10CytomX: Pullbacks Are Opportunities
Dec 14CytomX: Solving A Critical Problem In The High-Value ADC Space
Sep 15We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate
Aug 11Checking In On CytomX Therapeutics
Jun 13Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being
Jun 10CytomX EPS beats by $0.06, misses on revenue
May 06Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%
Mar 25Would Shareholders Who Purchased CytomX Therapeutics' (NASDAQ:CTMX) Stock Three Years Be Happy With The Share price Today?
Feb 02
How Much Of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Do Institutions Own?
Dec 29Here's Why We're Not At All Concerned With CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation
Dec 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$3m | US$652k | -US$569k |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$3m | US$623k | -US$99m |
| Sep 30 2022 | n/a | n/a | -US$149m |
| Jun 30 2022 | n/a | n/a | -US$143m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$4m | US$616k | -US$116m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$3m | US$595k | -US$65m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$76m |
| Dec 31 2019 | US$4m | US$575k | -US$133m |
| Sep 30 2019 | n/a | n/a | -US$99m |
| Jun 30 2019 | n/a | n/a | -US$99m |
| Mar 31 2019 | n/a | n/a | -US$83m |
| Dec 31 2018 | US$5m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$52m |
| Jun 30 2018 | n/a | n/a | -US$39m |
| Mar 31 2018 | n/a | n/a | -US$50m |
| Dec 31 2017 | US$3m | US$500k | -US$43m |
Compensation vs Market: Sean's total compensation ($USD2.61M) is above average for companies of similar size in the US market ($USD677.87K).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
CEO
Sean McCarthy (56 yo)
12.7yrs
Tenure
US$2,611,138
Compensation
Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 12.7yrs | US$2.61m | 0.78% $ 884.9k | |
| Senior VP & Chief Scientific Officer | 1.3yrs | US$1.21m | 0.088% $ 99.2k | |
| Senior VP | 3yrs | US$1.05m | 0.078% $ 88.4k | |
| Senior VP of Finance & Accounting | 2.7yrs | no data | 0.037% $ 42.4k | |
| Senior VP | 5.9yrs | US$1.21m | 0.096% $ 108.2k | |
| Senior VP & Chief Human Resources Officer | no data | no data | no data | |
| Senior Vice President of Intellectual Property | 5.2yrs | no data | no data | |
| Senior VP & Chief Medical Officer | less than a year | no data | no data | |
| Senior Vice President of Quality & Product Manufacturing | 1.3yrs | no data | no data | |
| Special Advisor to Chief Executive Officer | no data | US$273.54k | no data |
3.0yrs
Average Tenure
54yo
Average Age
Experienced Management: CTMX's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 12.7yrs | US$2.61m | 0.78% $ 884.9k | |
| Independent Director | 4.9yrs | US$75.12k | 0.0076% $ 8.6k | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.3yrs | US$76.98k | 0% $ 0 | |
| Independent Director | 5.3yrs | US$77.69k | 0% $ 0 | |
| Lead Independent Director | 8.6yrs | US$106.49k | 0% $ 0 | |
| Independent Director | 4yrs | US$80.62k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.3yrs | US$8.03m | no data | |
| Independent Director | 2.6yrs | US$68.89k | 0% $ 0 | |
| Member of Scientific Advisory Board | 4.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.3yrs | no data | no data |
4.3yrs
Average Tenure
59.5yo
Average Age
Experienced Board: CTMX's board of directors are considered experienced (4.3 years average tenure).